PharmaEngine (ROCO:4162) Moat Score: 0/10 (As of Jul. 13, 2026)


ROCO:4162 PharmaEngine Inc ROCO:4162
79 GF Score
Price NT$64.50
GF Value NT$115.46
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is PharmaEngine Moat Score?

PharmaEngine has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

PharmaEngine has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PharmaEngine might have No Moat - No discernible moat.

PharmaEngine  (ROCO:4162) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PharmaEngine Moat Score Related Terms

ROCO:4162
79GF Score
PharmaEngine Inc ROCO:4162
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PharmaEngine (ROCO:4162) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued. The current stock price of NT$64.50 is trading 44.1% below its estimated GF Value™ of NT$115.46. GuruFocus considers PharmaEngine to be Significantly Undervalued.

Key valuation signals for ROCO:4162:

  • Moat Score: 0
  • GF Value™: NT$115.46 vs. price of NT$64.50 (44.1% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmaEngine Business Description

Address No. 10, Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
79GF Score

Get the complete analysis for ROCO:4162

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$64.50
Price
NT$115.46
GF Value